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SUMMARY
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Objective. To evaluate the effi cacy of vaginal progesterone administration for preventing preterm birth and 
perinatal morbidity and mortality in asymptomatic women with a singleton gestation a nd a mid-trimester sono-
graphic cervical length (CL) < 25 mm.
Methods. This was an updated systematic review and meta-analysis of randomized controlled trials com-
paring the use of vaginal progesterone to placebo/no treatment in women with a singleton gestation and a mid-
trimester sonographic CL < 25 mm. Electronic databases, from their inception to May 2016, bibliographies and 
con ference proceedings were searched. The primary outcome measure was preterm birth < 34 weeks of gestation
or fetal death. Two reviewers independently selected studies, assessed the risk of bias and extracted the data.
Pooled relative risks (RRs) with 95% confi dence intervals (CI) were calculated.
Results. Five trials involving 974 women were included. A meta-analysis, including data from the OPPTI-
MUM study, showed that vaginal progesterone signifi cantly decreased the risk of preterm birth < 34 weeks of 
ges tation or fetal death compared to placebo (18.1% vs 27.5%; RR, 0.66 (95% CI, 0.52-0.83); P = 0.0005; fi ve
studies; 974 women). Meta-analyses of data from four trials (723 women) showed that vaginal proges terone ad-
ministration was associated with a statisti cally signifi cant reduction in the risk of preterm birth occurring at < 28
to < 36 gestational weeks (RRs from 0.51 to 0.79), respiratory distress syndrome (RR, 0.47 (95% CI, 0.27-0.81)),
composite neonatal morbidity and mortality (RR, 0.59 (95% CI, 0.38-0.91)), birth weight < 1500g (RR, 0.52 (95% 
CI, 0.34-0.81)) and admission to the neonatal intensive care unit (RR, 0.67 (95% CI, 0.50-0.91)). There were no
signifi cant differences in neurodevelopmental outcomes at 2 years of age between the vaginal progesterone and 
placebo groups.
Conclusion. This updated systematic review and meta- analysis reaffi rms that vaginal progesterone reduces
the risk of preterm birth and neonatal morbidity and mortality in women with a singleton gestation and a mid-tri-
mester CL < 25 mm, without any deleterious effects on neurodev- elopmental outcome. Clinicians should continue
to per form universal transvaginal CL screening at 18-24 weeks of gestation in women with a singleton gestation
and to offer vaginal progesterone to those with a CL < 25 mm. Published 2016. This article is a U.S. Government 
work and is in the public domain in the USA.
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Introduction
In 2013, preterm birth was the leading cause of 
both neonatal mortality (35% of 2.8 million deaths) 
and child mortality (17% of 6.3 million deaths) world-
wide1,2. Neonates born preterm are at increased risk 
of both short- term complications, attributed to im-
maturity of multiple organ systems3,4, and long-term
adverse health outcomes, such as neurodevelopmen-
tal disabilities4,5, behavioral problems3,4, childhood 
asthma6, cardiovascular disease7, diabetes8 and de-
pression9, in adult life. In addition, preterm birth is as-
sociated with a substantial economic cost and adverse
psychosocial and emotional effects on families3,4.
Preterm birth is a syndrome attributable to multiple 
pathological processes such as infection, vascular dis-
orders, decidual senescence, uterine overdistension, 
a decline in progesterone action, cervical disease, 
break down of maternal-fetal tolerance and stress, 
among others10-12. A short cervix, traditionally defi ned 
as a transvaginal sonographic cervical length (CL) < 
25 mm in the mid-trimester of pregnancy, is an impor-
tant risk factor for preterm birth and has emerged as 
one of the strongest and most consistent predictors of 
preterm birth in asymp tomatic women with a single-
ton or twin gestation13-27.
In 2012, an individual patient data (IPD) meta-
analysis evaluated the effi cacy and safety of vaginal 
progesterone administration for the prevention of 
preterm birth and neonatal morbidity and mortality in 
asymptomatic women with a sonographic short cer-
vix (CL < 25 mm) in the mid-trimester28. A total of 
723 women with a singleton gestation from four ran-
domized controlled trials (RCTs) were included in the 
study. Overall, the administration of vaginal proges-
terone signifi cantly reduced the risk of preterm birth 
occurring at < 28 to < 35 gestational weeks, as well 
as respiratory distress syndrome (RDS), composite 
neonatal morbidity and mortality, birth weight < 1500 
g and admission to the neonatal intensive care unit 
(NICU). Since then, authors and professional organi-
zations around the world have recommended the use 
of vaginal progesterone in patients with a singleton 
gestation and a short cervix in the mid-trimester29-42.
In addition, it has been suggested that the use of vagi-
nal progesterone in pregnant women with a short cer-
vix is one of the interventions that has contributed to 
the reduction in the rate of preterm birth in the USA in 
the last 7 years43.
Recently, the OPPTIMUM study44 tested the effect 
of vaginal progesterone in 1228 women at risk for pre-
term birth due to three major risk factors: (1) a history 
of spontaneous preterm birth; (2) a positive cervicov-
aginal fetal fi bronectin test combined with other clini-
cal risk factors for p reterm birth; or (3) a sonographic 
short cervix (CL < 25 mm). This double-blind, place-
bo-controlled trial reported that vaginal progesterone 
did not reduce the risk of preterm birth or neonatal 
morbidity and mortality in the entire population, or in
the subgroup of women with a CL < 25 mm, and has 
created confusion as to the effi cacy of vaginal proges-
terone in reducing the rate of preterm birth in women
with a short cervix45.
To address this issue, we updated the previous
system atic review and meta-analysis to quantify the
effi cacy of vaginal progesterone administration in
preventing preterm birth and perinatal morbidity and 
mortality in asymptomatic women with a singleton
gestation and a mid-trimester sonographic CL < 25
mm.
Methods
This study followed a prospective protocol and 
is reported in accordance with the Preferred Report-
ing Items for Systematic reviews and Meta-Analyses 
(PRISMA) statement46.
Data  sources and searches
A literature search was carried out in MEDLINE,
EMBASE, POPLINE, CINAHL and LILACS (all 
from inception to 31 May 2016), the Cochrane Central
Register of Controlled Trials and Research Registers
of ongoing trials, using a combination of keywords 
and text words related to progesterone (‘progester-
one’, ‘progestins’, ‘progestogen’, ‘progestagen’, ‘pro-
gestational agent’), preterm birth (‘preterm’, ‘prema-
ture’) and randomized controlled trial (‘randomized 
controlled trial’, ‘controlled clinical trial’). Google
Scholar, proceedings of congresses on obstetrics,
maternal-fetal medicine and ultrasound in obstetrics,
reference lists of identifi ed studies, previously pub-
lished systematic reviews and review articles were
also searched. In addition, we contacted investigators
involved in the fi eld to locate unpublished studies. No
language restrictions were applied.
Study selection
We included RCTs in which asymptomatic women
with a singleton gestation and a sonographic short cer-
vix (CL < 25 mm) in the mid-trimester were allocated 
randomly to receive vaginal progesterone or placebo/
no treatment for the prevention of preterm birth and/
or adverse perinatal outcomes. Trials were included 
if the primary aim of the study was to prevent pre-
term birth in women with a short cervix, or to prevent 
preterm birth in women with risk factors other than a
short cervix but for which outcomes were available
for women with a pre-randomization CL < 25 mm.
Exclusion criteria included quasirandomized trials, 
trials that evaluated vaginal progesterone in women
with multiple gestation, preterm labor, arrested pre-
term labor (as mainte nance tocolysis), premature
rupture of membranes or second-trimester bleeding,
trials that assessed vaginal pro gesterone in the fi rst 
trimester only to prevent miscarriage and studies that 
did not report clinical outcomes. Studies published as
abstracts alone were excluded if additional informa-
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tion on methodological issues and results could not be
obtained. When a study included women with single-
ton and multiple gestations it was not considered for 
inclusion in the review unless data for women with a
singleton gestation were extractable separately.
All published studies deemed suitable were re-
trieved and reviewed independently by two authors to
determine inclusion. Disagreements about inclusion
were resolved through discussion.
Outcome measures
The primary outcome measure of interest was pre-
term birth < 34 weeks of gestation or fetal death. Pre-
specifi ed secondary outcome measures included pre-
term birth < 37, < 36, < 35, < 34, < 33, < 32, < 30 and 
< 28 weeks of gestation; spontaneous preterm birth <
34 weeks of gestation; RDS; necrotizing enterocoli-
tis; intraventricular hemorrhage; proven neonatal sep-
sis; retinopathy of prematurity; fetal death; neonatal
death; perinatal death; a composite outcome of neona-
tal morbidity and mortality (defi ned as the occurrence 
of any of the following events: RDS, intraventricular 
hemorrhage, necrotizing enterocolitis, proven neona-
tal sepsis or neonatal death); birth weight < 1500 g 
and < 2500 g; admission to NICU; use of mechanical
ventilation; and long-term neurodevelopmental out-
comes.
Assessm ent of risk of bias
Two authors evaluated the risk of bias in each study
included in the meta-analysis using the Cochrane Col-
laboration tool for assessing risk of bias47. This tool
assesses seven domains related to risk of bias (ran-
dom sequence generation, allocation concealment,
blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selec-
tive reporting and other bias) and categorizes studies
by low, unclear or high risk of bias in each domain.
Discrepancies in the risk of bias assessment were re-
solved by consensus.
Data ex traction
One investigator extracted the relevant data from
eligible studies, which were then checked independ-
ently by another investigator. Information was ex-
tracted on study characteristics (randomization pro-
cedure, concealment allocation method, blinding of 
clinicians, women and outcome assessors, follow-up
period, completeness of outcome data for each out-
come, including attrition and exclusions from the
analysis, and intention-to-treat analysis), participants 
(inclusion and exclusion criteria, number of women
in randomized groups, baseline characteristics and 
country and date of recruitment), details of interven-
tion (aim, gestational age at trial entry, daily dose of 
vaginal progesterone, duration, compliance and use
of co-interventions) and outcomes (prespecifi ed out-
come measures, defi nition of outcome measures and 
the number of events and total number of participants 
in each group to calculate effect sizes).
We included additional data that had been obtained 
for four studies48-51 included in our previous IPD meta-
analysis28. Corresponding authors of three RCTs iden-
tifi ed in the new literature search were contacted by 
email to obtain additional data44,52,53. No author sup-
plied additional data. Disagreements regarding data
extraction were resolved by discussion among the
authors.
Data sy nthesis
The data synthesis was performed according to the
guidelines of the Cochrane Collaboration54. Outcomes 
were analyzed on an intention-to-treat basis. Re-
sults from different trials were combined to calculate 
pooled relative risk (RR) with 95% CIs for dichoto-
mous outcomes. Heterogeneity of the results among
studies was tested with the quantity I2 statistic55. A 
substantial level of heterogeneity was defi ned as I2
> 50%54,55. We pooled results from individual studies
using a fi xed-effect model if substantial statistical het-
erogeneity was not present. If I2 values were > 50%, 
a random-effects model was used to pool data across
studies. The number needed to treat (NNT) for benefi t 
or harm, with a 95% CI, was calculated for outcomes
for which there was a statistically signifi cant reduc-
tion or increase in risk difference based on control
event rates in the trials56.
Subgroup analyses were planned to assess pri-
mary and secondary outcome measures according to
several charac teristics such as CL, obstetric history, 
maternal age, race/ ethnicity, body mass index and 
daily dose of vaginal progesterone. However, the lim-
ited data reported in the OPPTIMUM study44 allowed 
only the performance of one subgroup analysis for 
the primary outcome measure according to the daily 
dose of vaginal progesterone. A test for interaction
between the treatment and subgroups was calculated 
to examine whether treatment effects differ between
subgroups57,58. An interaction P-value > 0.05 was 
considered to indicate that the effect of treatment did 
not differ signifi cantly between subgroups. We also
planned to explore potential sources of heterogeneity 
and to assess publication and related biases if at least 
10 studies were included in a meta-analysis, but these
analyses were not undertaken due to the small number 
of trials included in the review.
All statistical analyses were performed by using
the Review Manager (RevMan; version 5.3.5; The
Nordic Cochrane Centre, Copenhagen, Denmark) and 
StatsDirect (version 3.0.167; StatsDirect Ltd, Chesh-
ire, UK) statistical packages.
This systematic review and meta-analysis was ex-
empted for review by the IRB Administration Offi ce 
of Wayne State University because it involved the 
study of publicly available data sources and recorded 
data did not allow patient identifi cation.
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Results 
Selecti on, characteristics and risk of 
bias of studies
The searches produced 708 records,
of which 11 were considered relevant.
Figure 1 summarizes the process of iden-
tifi cation and selection of studies. Six
studies were excluded52,53,59-62. Five of 
these studies assessed vaginal proges-
terone in women at high risk for preterm
birth (previous preterm birth52,59-61, uter-
ine malformation52,59,61, cervical insuffi -
ciency or history of prophylactic cervical 
cerclage59,61, uterine leiomyoma52, ‘short 
cervix’52 and pregnancies conceived by
in-vitro fertilization or intracytoplasmic 
sperm injection62), but none reported re-
sults according to CL at randomization. 
The remaining study evaluated vaginal
progesterone in 80 Dutch women with a
singleton pregnancy, no previous sponta-
neous preterm birth < 34 weeks of ges-
tation and a CL<30mm at 18-22weeks, 
but did not report results for women with
a CL < 25 mm53. This study, which was 
stopped early due to low enrollment, re-
ported that vaginal progesterone was as-
sociated with a non-signifi cant reduction
in the risk of preterm birth < 34 weeks (RR, 0.81 (95% 
CI, 0.27-2.44)) and < 32 weeks (RR, 0.58 (95% CI, 
0.14-2.30)), and composite neonatal morbidity and 
mortality (RR, 0.47 (95% CI, 0.09-2.40)). Five stud-
ies, including 974 women with a CL < 25 mm, met the 
inclusion criteria44,48-51.
The main characteristics of the studies included 
in the systematic review are summarized in Table 1. 
All studies were double-blind, placebo-controlled 
trials, of which four were multicenter, conducted in 
hospitals from both developed and developing coun-
tries. Two trials were specifi cally designed to evalu-
ate the use of vaginal progesterone in women with a 
sonographic short cervix48,51, one evaluated the use 
of vaginal progesterone in women with a history of 
spontaneous preterm birth49, one examined the use 
of vaginal progesterone in women with a prior spon-
taneous preterm birth, uterine malformation or twin 
pregnancy50 and the remaining trial tested the effect 
of vaginal progesterone in women at risk of preterm 
birth because of previous spontaneous preterm birth 
< 34 weeks of gestation, or a sonographic CL < 25 
mm at 18-24 weeks, or a positive cervicovaginal 
fetal fi bronectin test combined with other clinical 
risk factors for preterm birth44. The two studies48,51 
specifi cally designed to assess the administration of 
vaginal progesterone in women with a short cervix 
provided 70% of the total sample size of the meta-
analysis.
Two studies used vaginal progesterone capsules
200 mg/ day44,48, two used vaginal progesterone gel
90 mg/day49,51 and the other used vaginal progesterone
suppositories 100 mg/day50. Treatment was started at 
24 weeks of gestation in two trials48,50, between 18 and 
22 weeks of gestation in one trial49, between 20 and 
23 weeks of gestation in another51 and between 22 and 
24 weeks of gestation in the remaining trial44. Three
studies reported that participants received study medi-
cation from the time of enrollment until 34 weeks of 
gestation44,48,50, and two administered treatment from
enrollment until 37 weeks of gestation49,51. The pri-
mary outcome measure differed among studies: spon-
taneous preterm birth < 34 weeks48, preterm birth < 32
+ 0 weeks49, preterm birth < 37 weeks50 and preterm
birth < 33 weeks51. The remaining study44 had three
primary outcome measures: preterm birth < 34 + 0 
weeks or fetal death; a composite outcome of neona-
tal death, bronchopulmonary dysplasia or brain injury 
assessed by neurosonography; and the Bayley-III cog-
nitive composite score at 2 years of age.
Figure 2 shows the risk of bias in each included 
study. All studies were judged to be at low risk for 
selection (random sequence generation and alloca-
tion concealment), performance (blinding of patients
and clinical staff) and detection (blinding of outcome
assessment) biases. All but the OPPTIMUM study44
had low risk of attrition (incomplete outcome data),
reporting (selective reporting) and other biases. The



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































OPPTIMUM study44 was considered to be at high risk 
of attrition bias because information on the Bayley-III
cognitive composite score at 2 years of age, one of 
the primary outcome measures, was available for only
~70% of children (869/1228 in the entire population
and 179/256 in the subgroup of women with a CL < 25
mm). High attrition rates may bias an observed effect, 
mainly if the rate of the outcome measure is relatively
low, as was ‘moderate-to-severe neurodevelopment 
impairment’ in the entire population (10.5%). Infor-
mation on the two other primary outcome measures
was available for > 95% of participants (97% for the
obstetric outcome and 96% for the neonatal outcome);
thus, there was no evidence of attrition bias for these
outcome measures. Moreover, this study was judged 
to be at high risk of reporting bias because the publi-
cation did not include results for key outcomes such
as preterm bi32, and < 28 weeks of gestation, RDS,
retinopathy of prematurity and birth weight < 1500 
g and < 2500 g, among others. In addition, most pri-
mary and secondary outcome measures were incom-
pletely reported for the three subgroups of women at 
risk of preterm birth so they cannot be included in the
meta-analyses. Finally, the OPPTIMUM study44 was
at high risk of compliance bias because only 68.6%
of women (66.3% in the vaginal progesterone group)
used at least 80% of study medication in comparison 
to 93.6% in the study by Fonseca et al.4S and 88.5% in
the study by Hassan et al.51. In RCTs, non-compliance 
or non-adherence can be one of the major barriers to 
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Figure 2. Risk of bias of studies included in the systematic review.
Risk of bias: , low; , unclear; , high.+
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Table 2.
Effect of vaginal progesterone on the risk of preterm birth and adverse perinatal outcomes
Figure 3. Forest plot of the effect of vaginal progesterone on the risk of preterm birth < 34 weeks
of gestation or fetal death.
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33/133 38/118 30.2 0.77 (0.52–1.14)
1/4 2/4 0.50 (0.07–3.55)
28/235 46/223 0.58 (0.37–0.89)
4/12 6/19 1.06 (0.37–2.98)
90/498 131/476 100.0 0.66 (0.52–0.83)
5 Test for heterogeneity: I
2 = 0~
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(95% CI) I2 (%) NNT (95% CI)
Primary outcome
Preterm birth ≤ 34 weeks or fetal death 544,48–51 90/498 131/476 0.66 (0.52–0.83) 0 11 (8–21)
Secondary outcome
Preterm birth < 34 weeks 448–51 53/365 88/358 0.60 (0.44–0.82) 0 10 (7–23)
Spontaneous preterm birth < 34 weeks 448–51 43/365 69/358 0.63 (0.44–0.88) 0 14 (9–43)
Preterm birth < 37 weeks 448–51 127/365 141/358 0.89 (0.74–1.08) 0 —
Preterm birth < 36 weeks 448–51 93/365 117/358 0.79 (0.63–0.99) 0 15 (8–306)
Preterm birth < 35 weeks 448–51 67/365 100/358 0.67 (0.51–0.87) 0 11 (7–28)
Preterm birth < 33 weeks 448–51 41/365 72/358 0.56 (0.40–0.80) 0 11 (8–25)
Preterm birth < 32 weeks 448–51 35/365 62/358 0.56 (0.38–0.82) 0 13 (9–32)
Preterm birth < 30 weeks 448–51 27/365 46/358 0.59 (0.37–0.92) 0 19 (12–97)
Preterm birth < 28 weeks 448–51 20/365 39/358 0.51 (0.31–0.85) 0 19 (13–61)
Respiratory distress syndrome 448–51 17/365 37/358 0.47 (0.27–0.81) 0 18 (13–51)
Necrotizing enterocolitis 448–51 5/365 6/358 0.88 (0.29–2.62) 0 —
Intraventricular hemorrhage 448–51 5/365 7/358 0.68 (0.22–2.13) 0 —
Proven neonatal sepsis 448–51 11/365 14/358 0.80 (0.37–1.74) 0 —
Retinopathy of prematurity 448–51 5/365 3/358 1.51 (0.40–5.69) 0 —
Fetal death 448–51 6/365 7/358 0.82 (0.28–2.40) 0 —
Neonatal death 448–51 6/365 11/358 0.53 (0.20–1.39) 0 —
Perinatal death 448–51 12/365 18/358 0.64 (0.31–1.31) 0 —
Composite neonatal morbidity/mortality* 448–51 29/365 49/358 0.59 (0.38–0.91) 0 18 (12–81)
Birth weight < 1500 g 448–51 28/364 53/355 0.52 (0.34–0.81) 0 14 (10–35)
Birth weight < 2500 g 448–51 102/364 117/355 0.86 (0.69–1.07) 0 —
Admission to NICU 448–51 59/365 87/358 0.67 (0.50–0.91) 0 12 (8–46)
Mechanical ventilation 448–51 28/365 43/358 0.65 (0.41–1.01) 0 —
*Occurrence of any of the following events: respiratory distress syndrome; intraventricular hemorrhage; necrotizing enterocolitis; proven
neonatal sepsis; neonatal death. CI, confidence interval; NICU, neonatal intensive care unit; NNT, number needed to treat; RR, relative risk.
Primary outcom e
Vaginal progesterone administered to patients with
a transvaginal sonographic short cervix was associat-
ed with a signifi cant reduction in the risk of preterm
birth < 34 weeks of gestation or fetal death (18.1% vs
27.5%; RR, 0.66 (95% CI, 0.52-0.83); P = 0.0005; I2
= 0%; fi ve studies, 974 women; Table 2 and Figure 3).
The number of patients needed to treat with vaginal
pro gesterone to prevent one case of preterm birth < 
34 weeks of gestation or fetal death was 11 (95% CI,
8-21).
A signifi cant decrease in the risk of preterm birth 
< 34 weeks of gestation or fetal death was found in
women who received either 90-100 mg/day (RR, 0.62 
(95% CI, 0.42-0.91); I2 = 0%; three studies, 497 wom-
en) or 200 mg/day (RR, 0.69 (95% CI, 0.51-0.92); I2
34
= 0%; two studies, 477 women) of vaginal progester-
one. The interaction effect of vaginal progesterone
based on daily dose was non-signifi cant (P = 0.65).
Secondary outc omes
All pooled estimates of the effects of vaginal
proges terone on secondary outcome measures were
obtained by the meta-analysis of data from four tri-
als48-51 (Table 2). Treatment with vaginal progester-
one was associated with a signifi cantly lower risk of 
preterm birth < 36 weeks (RR, 0.79 (95% CI, 0.63-
0.99)), < 35 weeks (RR, 0.67 (95% CI, 0.51-0.87)), <
34 weeks (RR, 0.60 (95% CI, 0.44-0.82)), < 33 weeks
(RR, 0.56 (95% CI, 0.40-0.80)), < 32 week and < 28
weeks (RR, 0.51 (95% CI, 0.31-0.85)), spon taneous
preterm birth < 34 weeks (RR, 0.63 (95% CI, 0.44-
0.88)); RDS (RR, 0.47 (95% CI, 0.27-0.81)); compos-
ite neonatal morbidity and mortality (RR, 0.59 (95%
CI, 0.38-0.91)); birth weight < 1500 g (RR, 0.52 (95%
CI, 0.34-0.81)) and admission to NICU (RR, 0.67
(95% CI, 0.50-0.91)). The NNT to prevent one case
of preterm birth occurring at < 28 to < 36 gestational
weeks or adverse neonatal outcomes varied from 10-
19. There were no signifi cant differences between the
two groups for risk of preterm birth < 37 weeks of 
gestation, necro- tizing enterocolitis, intraventricu-
lar hemorrhage, proven neonatal sepsis, retinopathy
of prematurity, fetal death, neonatal death, perinatal
death, birth weight < 2500 g and use of mechanical
ventilation.
The OPPTIMUM study44 reported that infants
whose mothers received vaginal progesterone had a
non-signifi cant decreased risk of a composite outcome
of neonatal death, bronchopulmonary dysplasia or 
brain injury (odds ratio, 0.54 (95% CI, 0.25-1.16); P =
0.113; 246 infants). The Bayley-III cognitive compos-
ite scores at 2 years of age did not differ signifi cantly
between the vaginal progesterone and placebo groups




This updated systematic review and meta-analy-
sis, which includes data reported by the OPPTIMUM
study44, shows t hat vaginal progesterone signifi cantly
decreases the risk of preterm birth < 34 weeks of ges-
tation or fetal death by 34%, among women with a
singleton gestation and a mid-trimester CL < 25 mm.
Clearly, the reduction in this composite outcome is at-
tributable to a decrease in preterm birth < 34 weeks
of gestation rather than fetal death because vaginal
progesterone had no effect on the risk of this adverse
outcome in either the meta-analysis of data from four 
studies (RR, 0.82 (95% CI, 0.28-2.40)) or in the OPP-
TIMUM study44 (RR, 1.14 (95% CI, 0.41-3.12) for 
the entire population). In addition, pooled estimates
obtained by combining data from four trials indicate
that vaginal progesterone administration was associ-
ated with a statistically signifi cant reduction in the
risk of preterm birth occurring at gestational ages of <
28 to < 36 weeks, RDS, composite neonatal morbidity
and mortality, birth weight < 1500 g and admission to
NICU.
Unfortunately, it was not possible to update most 
endpoints assessed in our previous meta-analysis28 be-
cause the OPPTIMUM study44 did not report data for 
most adverse pregnancy and neonatal outcomes. It is
noteworthy that the OPPTIMUM study44 was under-
powered to detect a meaningful difference between
vaginal progesterone and placebo in the subgroup of 
women with a CL < 25 mm. Indeed, this study had 
a post-hoc statistical power of only 26% to detect a
23% reduction in the risk of preterm birth < 34 weeks 
of gestation or fetal death (from 32.2% in the placebo
group to 24.8% in the vaginal progesterone group)
and 33% to detect a 42% reduction in the risk of the
composite outcome of neonatal morbidity and mortal-
ity (from ~14% in the placebo group to ~8% in the
vaginal progesterone group) at an a-level (two-sided)
of 0.05. Nonetheless, in this subpopulation, the OPP-
TIMUM study reported a non-signifi cant ~42% reduc-
tion in the risk of neonatal death or serious neonatal
morbidity, which is very similar to the 41% signifi cant 
reduction in the risk of composite neonatal morbidity
and mortality found in the meta-analysis of data from
the other four trials48-51.
To explore the consequences of the lack of data
in the OPPTIMUM study publication44, we performed 
several simulated meta-analyses by using denomina-
tors of vaginal progesterone and placebo groups in the
subgroup of women with a CL < 25 mm reported in
this study.
In summary, we found that the statistically signifi -
cant benefi cial effects of vaginal progesterone admin-
istration on the risk of preterm birth < 35, < 33, < 32, <
30, and < 28 weeks of gestation, RDS, composite neo-
natal morbidity and mortality, birth weight < 1500 g
and admission to NICU obtained in the meta-analyses
of data from four trials could only become non-sta-
tistically signifi cant if the rates of these adverse out-
comes in the OPPTIMUM study44 were higher in the
vaginal progesterone group than in the placebo group,
and the RRs were > 1.12 for most of these outcomes.
This hypo thetical scenario is unlikely, given that the
OPPTIMUM study44 showed a clear trend towards re-
duction in the risk of preterm birth < 34 weeks of ges-
tation (23%) and neonatal death or serious neonatal
morbidity (~42%) associated with the use of vaginal
progesterone.
With regard to the effect of vaginal progesterone
on the risk of adverse neurodevelopmental outcomes,
the OPPTIMUM study44 found that there were no sig-
nifi cant differences in the mean Bayley-III cognitive 
composite scores or rates of neurodevelopmental im-
pairment at 2 years of age between children exposed
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in utero to vaginal progesterone and those exposed to
placebo. Similar fi ndings were reported by O’Brien
et al.64 who assessed neurodevelopmental outcomes
among children born to women enrolled in their trial49
using the Denver II Developmental Screening Test at 
6 months of age (445 children), 12 months of age (389
children) and 24 months of age (293 children). There
was no signifi cant difference in the rate of suspected 
developmental delay at any time during the 24-month
follow-up between the vaginal progesterone and pla-
cebo groups. These fi ndings are in accordance with
those reported in children whose mothers participated 
in RCTs of vaginal progesterone vs placebo for the
prevention of preterm birth in twin gestation65,66. Rode
et al.65 reported that the mean Ages and Stages Ques-
tionnaire scores (a tool that measures neurodevelop-
mental disability) at 6 months (1050 children) and 18
months (991 children) of age were not signifi cantly
different between the two groups, whereas McNamara
et al.66 reported that there was no signifi cant difference
in neurodevelopmental outcomes (assessed using the
Child Development Inventory tool) between twins in
the vaginal progesterone and placebo groups at 3-6
years of age (759 children). In conclusion, the current 
available evidence suggests that in-utero exposure to
vaginal progesterone has no impact on neurodevelop-
mental outcomes at least until 2 years of age, and pos-
sibly until 6 years of age.
Strengths and limitations
The reliability and robustness of the results ob-
tained in this updated review are supported by: (1) the
use of the  most rigorous methodology for perform-
ing a systematic review and meta-analysis of RCTs;
(2) the extensive liter ature searches without language
restrictions; (3) the strict assessment of methodologi-
cal quality of included trials based on widely recom-
mended criteria; (4) the quantita tive way of summa-
rizing the evidence; (5) the evidence of clinical and 
statistical homogeneity in the meta-analyses of all 
outcome measures evaluated; (6) the relatively nar-
row CIs obtained that made our estimates of effect 
size more precise; and (7) the subgroup analysis that 
did not show any signifi cant infl uence of daily dose
of vaginal progesterone on effect size. The main lim-
itation of our study was the lack of data on several
secondary outcome measures that were not reported 
in the OPPTIMUM study publication44. However, as
mentioned previously, it is very unlikely that the sig-
nifi cant benefi cial effects of vagi nal progesterone on
the risk of preterm birth and neonatal morbidity and 
mortality become non-signifi cant after the inclusion
of data from this study in the meta-analyses.
Implications for practice and research
Evidence from this updated meta-analysis reaf-
fi rms that vaginal progesterone reduces the risk of 
prete rm birth < 34 weeks of gestation in women with
a singleton gestation and a mid-trimester CL < 25
mm. Therefore, clinicians should continue to perform
universal transvagi- nal CL screening at 18-24 weeks 
of gestation in women with a singleton gestation, and 
to offer vaginal proges terone to those with a CL < 25
mm, regardless of their history of spontaneous pre-
term birth, with the goal of preventing preterm birth
and reducing neonatal morbid ity and mortality. This
recommendation is buttressed by the safety margin of 
vaginal progesterone44,64-66 and the cost-effectiveness
of the intervention67-74. We believe that an IPD meta-
analysis including data from the OPPTI MUM trial44
and the Dutch study53 is warranted to enable a more
rigorous analysis and the performance of several sub-
group analyses. We have invited the investigators of 
these trials to participate in such a study.
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